Follitropin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Follitropin: From Infertility Treatment to Allergic Asthma
One-Sentence Summary
Follitropin is a recombinant follicle-stimulating hormone (FSH) used in fertility treatment. The TxGNN model predicts it may be effective for allergic asthma, but this is a computational prediction only, with 0 clinical trials and 0 publications supporting it. The evidence is at the model-prediction level.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the Singapore registration data. Published literature and pharmacology data describe use in female infertility and ovulation induction. |
| Predicted New Indication | Allergic asthma |
| TxGNN Prediction Score | 96.32% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 11 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Follitropin is a recombinant form of FSH. It acts on FSH receptors (FSHR) in gonadal tissue and is used in assisted reproduction and ovulation induction.
No established mechanistic link connects FSH receptor signalling to allergic airway inflammation. The high TxGNN score is a knowledge-graph prediction and is not backed by any trial or publication. Other top predictions (intrinsic asthma, Prinzmetal angina, chromosomal deletion syndromes, orofacial clefting syndrome and others) also have no plausible mechanism and no supporting evidence. They likely reflect graph-structure artefacts rather than true therapeutic potential.
Among all ten predicted indications, only "headache disorder" has a related article. That article is a case report of migraine-like symptoms after follitropin beta injection, which points to a possible side effect rather than a therapeutic effect.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for allergic asthma.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13023P | Gonal-f 300 iu/0.48 ml pre-filled pen | Solution for injection | Not specified |
| SIN13022P | Gonal-f 450 iu/0.72 ml pre-filled pen | Solution for injection | Not specified |
| SIN14474P | Puregon solution for injection 900IU/1.08ml | Injection | Not specified |
| SIN14473P | Puregon solution for injection 600IU/0.72ml | Injection | Not specified |
| SIN12185P | Puregon solution for injection 300 iu/0.36 ml | Injection | Not specified |
The data lists 11 valid registrations in total, all single-ingredient. Six are Gonal-f and Puregon products, and five are Pergoveris products. Only the first five are shown here.
Safety Considerations
- Drug Interactions:
- Ganirelix: Moderate interaction (DDInter).
- FSH receptor: this is a pharmacological target relationship, not a drug interaction.
- Case report signal: One case report (PMID 29734531) describes migraine-like symptoms immediately after recombinant follitropin beta injection.
- Other literature: Published reviews note that ovarian hyperstimulation syndrome and multiple pregnancy are risks of FSH-based ovulation induction.
Please refer to the package insert for full warnings and contraindications. These were not available in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a knowledge-graph score. There are no clinical trials or publications, and no plausible mechanism linking FSH signalling to allergic airway disease. The other nine predicted indications are equally unsupported. The package insert safety data are also missing.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website
- Detailed mechanism of action data (e.g. from DrugBank)
- Any mechanistic or preclinical evidence linking FSH signalling to airway inflammation
- Confirmation of the approved indications for each Singapore registration
- A route and dosage-form compatibility assessment, as the current data show injectable forms only
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.